0001642380falseQ2--12-31http://fasb.org/us-gaap/2024#GainLossOnSaleOfOtherAssetshttp://imdxinc.com/20250630#ChiefExecutiveOfficerAndChiefFinancialOfficerMember0001642380srt:EuropeMember2025-06-300001642380imdx:SalesAgreementMember2024-08-092024-08-090001642380imdx:BioRadLaboratoriesIncMemberimdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2024-04-152024-04-150001642380us-gaap:SalesRevenueNetMemberimdx:CompanyAMemberus-gaap:CustomerConcentrationRiskMember2024-04-012024-06-300001642380us-gaap:FairValueInputsLevel3Memberimdx:MeasurementInputManagementProbabilityEstimateMemberimdx:InsightGeneticsIncMembersrt:MaximumMember2025-06-300001642380imdx:ChronixMergerMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2025-01-012025-06-300001642380us-gaap:SeriesAPreferredStockMemberimdx:RegisteredDirectOfferingMember2023-04-042023-04-050001642380imdx:OfficeLeaseAgreementMember2021-06-212021-06-210001642380country:GB2025-06-300001642380us-gaap:FairValueInputsLevel3Memberimdx:InsightGeneticsIncMember2024-06-300001642380imdx:DetermaIOMember2023-01-012023-03-310001642380us-gaap:CommonStockMember2024-04-012024-06-3000016423802025-08-040001642380imdx:ChronixAcquisitionMember2024-01-012024-12-310001642380us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-06-300001642380us-gaap:AccountsPayableMemberimdx:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-12-310001642380us-gaap:FairValueInputsLevel3Memberimdx:InsightGeneticsIncMembersrt:MaximumMemberus-gaap:MeasurementInputExpectedTermMember2025-01-012025-06-300001642380imdx:DetermaCNIMemberimdx:MPEEMValuationApproachMember2024-01-012024-12-310001642380us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001642380imdx:BroadwoodPartnersLPMemberimdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2025-02-102025-02-100001642380imdx:SecuritiesPurchaseAgreementMemberimdx:SeriesARedeemableConvertiblePreferredStockMember2024-04-152024-04-150001642380imdx:TwoThousandEighteenIncentivePlanMember2024-12-310001642380us-gaap:SellingAndMarketingExpenseMember2025-01-012025-06-300001642380country:US2024-04-012024-06-300001642380imdx:BioRadLaboratoriesIncMemberimdx:LaboratoryEquipmentMember2024-06-300001642380us-gaap:ResearchAndDevelopmentExpenseMember2025-04-012025-06-300001642380srt:EuropeMember2024-01-012024-06-300001642380country:GB2025-01-012025-06-3000016423802024-06-300001642380us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001642380imdx:KittedProductsMembersrt:MaximumMember2025-06-3000016423802024-04-052024-04-050001642380imdx:PerformanceBasedOptionsMember2023-08-310001642380imdx:SecuritiesPurchaseAgreementMember2025-02-102025-02-100001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2025-01-012025-06-300001642380imdx:SecuritiesPurchaseAgreementMemberimdx:PreFundedWarrantMember2025-06-300001642380us-gaap:SalesRevenueNetMemberimdx:CompanyBMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberimdx:LaboratoryDevelopedTestServicesMember2025-04-012025-06-300001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberimdx:LaboratoryDevelopedTestServicesMember2025-01-012025-06-300001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2024-10-042024-10-040001642380imdx:LeaseAgreementMember2024-01-012024-01-310001642380us-gaap:RetainedEarningsMember2025-04-012025-06-300001642380imdx:OperatingAndFinancingLeasesMember2024-12-310001642380imdx:ChronixMergerMemberus-gaap:FairValueInputsLevel3Member2024-01-012024-06-300001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:PatrickWSmithMember2024-10-042024-10-040001642380us-gaap:ValuationTechniqueDiscountedCashFlowMemberimdx:InsightGeneticsIncMember2025-01-012025-06-300001642380us-gaap:CustomerRelationshipsMember2025-01-012025-06-300001642380imdx:ChronixMergerMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMembersrt:MaximumMember2025-06-300001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMembercountry:US2024-04-012024-06-300001642380imdx:RazorStockPurchaseAgreementMemberimdx:RazorGenomicsIncMember2023-02-152023-02-160001642380imdx:DetermaIOMember2024-01-012024-12-310001642380us-gaap:FairValueInputsLevel3Memberimdx:MeasurementInputManagementProbabilityEstimateMemberimdx:InsightGeneticsIncMembersrt:MaximumMember2024-06-300001642380imdx:KittedProductsMember2025-01-012025-06-300001642380imdx:SubleasePeriodFourMemberimdx:OfficeSubleaseAgreementMember2025-01-012025-06-300001642380us-gaap:SalesRevenueNetMemberimdx:CompanyDMemberus-gaap:CustomerConcentrationRiskMember2024-04-012024-06-300001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMembercountry:US2025-04-012025-06-300001642380imdx:BioRadLaboratoriesIncMemberimdx:LaboratoryEquipmentMember2025-06-300001642380us-gaap:PreferredStockMemberimdx:SeriesARedeemableConvertiblePreferredStockMember2024-01-012024-06-300001642380us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberimdx:OutsideOfUnitedStatesMember2025-01-012025-06-300001642380imdx:MonteCarloValuationTechniqueMembersrt:MaximumMember2023-08-012023-08-310001642380us-gaap:CommonStockMember2024-01-012024-06-300001642380us-gaap:SellingAndMarketingExpenseMember2024-01-012024-06-300001642380imdx:SubleasePeriodOneMemberimdx:OfficeSubleaseAgreementMember2025-01-012025-06-300001642380imdx:PerformanceBasedRestrictedStockUnitsMemberimdx:MonteCarloValuationTechniqueMember2024-10-012024-10-310001642380us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMembersrt:MinimumMemberimdx:InsightGeneticsIncMember2025-06-3000016423802024-12-310001642380imdx:InvestorRelationsConsultingServiceArrangementMember2024-04-012024-06-300001642380imdx:LaboratoryDevelopedTestServicesMember2024-01-012024-06-300001642380us-gaap:ShareBasedCompensationAwardTrancheTwoMemberimdx:PerformanceBasedRestrictedStockUnitsMember2024-10-012024-10-310001642380us-gaap:CommonStockMember2025-04-012025-06-300001642380imdx:InvestorRelationsConsultingServiceArrangementMember2024-01-012024-06-300001642380imdx:LaboratoryServicesMember2025-04-012025-06-300001642380us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberimdx:InsightGeneticsIncMembersrt:MaximumMember2024-06-300001642380imdx:MPCHoldingsLLCMemberimdx:LeaseAgreementMember2024-01-310001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberimdx:LaboratoryServicesMember2025-04-012025-06-300001642380imdx:LaboratoryDevelopedTestServicesMember2024-04-012024-06-300001642380imdx:SecuritiesPurchaseAgreementMemberimdx:PreFundedWarrantMember2025-02-102025-02-100001642380us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2024-10-042024-10-040001642380imdx:ChronixMergerMemberus-gaap:FairValueInputsLevel3Membersrt:MaximumMemberus-gaap:MeasurementInputExpectedTermMember2025-01-012025-06-300001642380imdx:TwoThousandTenStockOptionPlanMember2025-06-300001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:PatrickWSmithMember2025-02-102025-02-100001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2024-04-1500016423802025-05-310001642380imdx:SecuritiesPurchaseAgreementMemberimdx:PreFundedWarrantMember2024-04-152024-04-150001642380srt:AsiaPacificMember2025-01-012025-06-300001642380imdx:PuraVidaMemberimdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2023-04-032023-04-030001642380us-gaap:FairValueInputsLevel3Memberimdx:InsightGeneticsIncMember2025-01-012025-06-300001642380us-gaap:FairValueInputsLevel3Memberimdx:ChronixMergerMembersrt:MinimumMemberus-gaap:MeasurementInputExpectedTermMember2024-01-012024-06-300001642380imdx:SeriesARedeemableConvertiblePreferredStockMember2022-04-132022-04-130001642380us-gaap:SalesRevenueNetMemberimdx:CompanyAMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-06-300001642380us-gaap:WarrantMember2024-01-012024-06-300001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberimdx:KittedProductsMember2025-04-012025-06-300001642380us-gaap:FairValueInputsLevel3Memberimdx:ChronixMergerMemberus-gaap:MeasurementInputDiscountRateMembersrt:MinimumMember2024-06-300001642380imdx:BroadwoodPartnersLPMemberimdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2023-04-032023-04-030001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:ArnoMember2023-04-032023-04-030001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:AWMMember2023-04-032023-04-030001642380us-gaap:AccountsPayableMemberimdx:CustomerOneMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-06-300001642380imdx:PerformanceBasedOptionsMember2023-08-012023-08-310001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:AWMMember2025-02-102025-02-100001642380us-gaap:FairValueInputsLevel3Membersrt:MinimumMemberimdx:InsightGeneticsIncMemberus-gaap:MeasurementInputExpectedTermMember2025-01-012025-06-300001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberimdx:LaboratoryServicesMember2025-01-012025-06-3000016423802025-01-012025-06-300001642380imdx:OncocyteCorporationMember2025-01-012025-06-300001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2024-10-040001642380us-gaap:FairValueInputsLevel3Membersrt:MinimumMemberimdx:InsightGeneticsIncMemberus-gaap:MeasurementInputExpectedTermMember2024-01-012024-06-300001642380us-gaap:CommonStockMember2025-02-100001642380imdx:UnderwrittenOfferingMemberimdx:UnderwritersMemberimdx:BroadwoodCapitalLPMember2022-04-130001642380us-gaap:CustomerRelationshipsMember2025-06-300001642380country:GB2024-04-012024-06-300001642380imdx:TwoThousandTenStockOptionPlanMember2024-12-310001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberimdx:LaboratoryServicesMember2024-04-012024-06-300001642380us-gaap:CommonStockMember2024-04-150001642380us-gaap:SalesRevenueNetMemberimdx:CompanyAMemberus-gaap:CustomerConcentrationRiskMember2025-04-012025-06-300001642380imdx:ExecutiveOfficersMember2024-01-012024-12-310001642380imdx:InsightGeneticsIncMemberimdx:RoyaltyTwoMember2025-06-300001642380us-gaap:StockOptionMember2025-04-012025-06-300001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2025-04-012025-06-300001642380us-gaap:StockOptionMember2024-04-012024-06-300001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2025-02-102025-02-100001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2025-02-100001642380imdx:DetermaCNIMemberimdx:MPEEMValuationApproachMember2024-12-310001642380us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2024-04-152024-04-150001642380imdx:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-06-300001642380imdx:PerformanceBasedOptionsMember2024-10-012024-10-310001642380us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-300001642380imdx:LaboratoryServicesMember2024-01-012024-06-300001642380imdx:PerformanceBasedOptionsMember2024-10-310001642380us-gaap:SalesRevenueNetMemberimdx:CompanyAMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001642380srt:EuropeMember2025-01-012025-06-300001642380country:US2024-12-310001642380imdx:SeriesARedeemableConvertiblePreferredStockMember2022-04-130001642380imdx:LifeTechnologiesCorporationMember2025-01-012025-06-300001642380imdx:LaboratoryServicesMember2025-01-012025-06-300001642380imdx:InsightGeneticsIncMemberimdx:MilestoneOneMember2025-06-300001642380imdx:LaboratoryServicesMember2024-01-012024-06-300001642380us-gaap:RetainedEarningsMember2024-12-310001642380us-gaap:MachineryAndEquipmentMembersrt:MaximumMember2025-06-300001642380srt:AsiaPacificMember2024-04-012024-06-300001642380imdx:ChronixMergerMember2024-06-300001642380us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001642380imdx:OfficeSubleaseAgreementMember2023-08-082023-08-080001642380us-gaap:EquipmentMembersrt:MaximumMember2025-06-300001642380us-gaap:FairValueInputsLevel3Memberimdx:ChronixMergerMember2023-12-310001642380imdx:PerformanceBasedRestrictedStockUnitsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMemberimdx:MonteCarloValuationTechniqueMember2024-10-012024-10-310001642380imdx:MergerAgreementMemberimdx:ChronixEquityMember2023-02-072023-02-080001642380us-gaap:FairValueInputsLevel3Membersrt:MinimumMemberimdx:MeasurementInputManagementProbabilityEstimateMemberimdx:InsightGeneticsIncMember2025-06-300001642380us-gaap:CommonStockMember2024-06-300001642380us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001642380us-gaap:CustomerRelationshipsMember2024-01-012024-12-310001642380us-gaap:InProcessResearchAndDevelopmentMemberimdx:DetermaIOMember2025-01-012025-06-300001642380imdx:LaboratoryDevelopedTestServicesMember2025-04-012025-06-300001642380imdx:CostOfRevenuesMember2025-04-012025-06-300001642380imdx:MonthlyRentMemberimdx:OfficeSubleaseAgreementMember2025-01-012025-06-300001642380imdx:BroadwoodPartnersLPMemberimdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2024-04-152024-04-150001642380imdx:LaboratoryDevelopedTestServicesMember2024-04-012024-06-300001642380us-gaap:StockOptionMember2025-01-012025-06-300001642380srt:EuropeMember2024-12-310001642380us-gaap:GeneralAndAdministrativeExpenseMember2025-04-012025-06-300001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2023-04-032023-04-030001642380us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2024-04-150001642380imdx:LaboratoryServicesMember2024-12-310001642380imdx:DetermaCNIMemberimdx:MPEEMValuationApproachMember2025-01-012025-06-300001642380imdx:KittedProductsMember2024-01-012024-06-300001642380imdx:JamesMemberimdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2025-02-102025-02-100001642380imdx:KittedProductsMember2024-04-012024-06-300001642380imdx:PerformanceBasedRestrictedStockUnitsMember2024-10-310001642380us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001642380us-gaap:FairValueInputsLevel3Membersrt:MinimumMemberimdx:MeasurementInputManagementProbabilityEstimateMemberimdx:InsightGeneticsIncMember2024-06-300001642380imdx:DragonScientificLLCMemberimdx:RazorStockPurchaseAgreementMemberimdx:RazorGenomicsIncMember2022-12-150001642380imdx:OfficeSubleaseAgreementMember2025-01-012025-06-300001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:ArnoMember2024-04-152024-04-150001642380us-gaap:PreferredStockMemberimdx:SeriesARedeemableConvertiblePreferredStockMember2023-12-310001642380us-gaap:PreferredStockMemberimdx:SeriesARedeemableConvertiblePreferredStockMember2024-03-310001642380imdx:JamesMemberimdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2024-10-042024-10-040001642380imdx:ChronixAcquisitionMember2025-01-012025-06-300001642380imdx:ExecutiveOfficersMember2025-01-012025-06-300001642380imdx:UnderwrittenOfferingMemberus-gaap:CommonStockMemberimdx:PuraVidaInvestmentsLLCMember2022-04-122022-04-130001642380imdx:LaboratoryServicesMember2024-04-012024-06-300001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:ShareBasedCompensationAwardTrancheOneMemberimdx:SeriesARedeemableConvertiblePreferredStockMember2022-04-122022-04-130001642380imdx:OperatingAndFinancingLeasesMember2025-06-300001642380us-gaap:PreferredStockMemberimdx:InterestMemberimdx:SeriesARedeemableConvertiblePreferredStockMember2022-04-130001642380imdx:RoyaltyOneMemberimdx:InsightGeneticsIncMember2025-06-300001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:AWMMember2024-10-042024-10-040001642380imdx:BioRadLaboratoriesIncMember2024-12-310001642380imdx:RazorGenomicsIncMember2021-02-230001642380us-gaap:FairValueInputsLevel3Memberimdx:InsightGeneticsIncMember2024-01-012024-06-3000016423802025-06-300001642380us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001642380imdx:KittedProductsMember2025-04-012025-06-300001642380srt:MinimumMemberimdx:MonteCarloValuationTechniqueMember2023-08-012023-08-310001642380imdx:SecuritiesPurchaseAgreementMemberimdx:PreFundedWarrantMember2024-04-150001642380us-gaap:SellingAndMarketingExpenseMember2025-04-012025-06-300001642380us-gaap:InProcessResearchAndDevelopmentMemberimdx:DetermaIOMember2024-01-012024-12-310001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2024-04-012024-06-300001642380imdx:MPCHoldingsLLCMemberimdx:LeaseAgreementMember2025-01-012025-06-300001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:AWMMember2024-04-152024-04-150001642380imdx:MilestoneThreeMemberimdx:InsightGeneticsIncMember2025-06-300001642380us-gaap:WarrantMember2025-04-012025-06-300001642380us-gaap:MachineryAndEquipmentMembersrt:MinimumMember2025-06-300001642380imdx:DragonScientificLLCMemberimdx:RazorStockPurchaseAgreementMemberimdx:RazorGenomicsIncMember2022-12-152022-12-150001642380srt:MinimumMember2025-06-300001642380srt:AsiaPacificMember2025-04-012025-06-300001642380imdx:UnderwrittenOfferingMemberimdx:BroadwoodCapitalLPMember2022-04-130001642380us-gaap:CommonStockMember2024-03-310001642380us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-06-300001642380imdx:BioRadLaboratoriesIncMember2025-06-300001642380imdx:LaboratoryDevelopedTestServicesMember2025-01-012025-06-300001642380imdx:LaboratoryServicesMember2024-04-012024-06-300001642380us-gaap:PreferredStockMemberimdx:SeriesARedeemableConvertiblePreferredStockMember2024-04-012024-06-300001642380us-gaap:StockOptionMember2024-01-012024-06-300001642380imdx:SalesAgreementMember2024-08-090001642380imdx:TwoThousandEighteenIncentivePlanMember2025-06-272025-06-270001642380imdx:SecuritiesPurchaseAgreementMember2024-04-152024-04-150001642380imdx:ChronixMember2025-01-012025-06-3000016423802024-10-012024-10-310001642380us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-300001642380imdx:TwoThousandEighteenIncentivePlanMember2025-06-300001642380us-gaap:RetainedEarningsMember2023-12-310001642380imdx:InsightGeneticsIncMemberimdx:MilestoneTwoMember2025-06-300001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMembersrt:MaximumMember2024-10-040001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberimdx:OutsideOfUnitedStatesMember2025-04-012025-06-300001642380imdx:TwoThousandTenPlanAndTwoThousandEighteenIncentivePlanActivityMember2024-01-012024-06-300001642380country:GB2024-01-012024-06-300001642380imdx:ChronixMergerMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMembersrt:MaximumMember2024-06-300001642380us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001642380imdx:LaboratoryDevelopedTestServicesMember2025-04-012025-06-300001642380imdx:DragonScientificLLCMemberimdx:RazorStockPurchaseAgreementMemberimdx:RazorGenomicsIncMember2023-02-1600016423802024-03-310001642380us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-06-300001642380us-gaap:AccountsPayableMemberus-gaap:CustomerConcentrationRiskMemberimdx:CustomerTwoMember2024-01-012024-12-310001642380country:GB2025-04-012025-06-300001642380imdx:CostOfRevenuesMember2024-04-012024-06-300001642380imdx:PerformanceBasedRestrictedStockUnitsMemberimdx:MonteCarloValuationTechniqueMember2025-01-012025-06-300001642380imdx:SecuritiesPurchaseAgreementMember2024-10-042024-10-040001642380us-gaap:FairValueInputsLevel3Memberimdx:InsightGeneticsIncMember2025-06-300001642380us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-300001642380country:US2025-01-012025-06-300001642380us-gaap:AccountsPayableMemberus-gaap:CustomerConcentrationRiskMemberimdx:CustomerTwoMember2025-01-012025-06-300001642380imdx:LaboratoryServicesMember2025-04-012025-06-300001642380us-gaap:CommonStockMember2023-12-310001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2024-04-152024-04-150001642380us-gaap:RetainedEarningsMember2024-06-300001642380imdx:BioRadLaboratoriesIncMemberimdx:LaboratoryEquipmentMember2024-01-012024-06-300001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMembercountry:US2025-01-012025-06-300001642380imdx:MonteCarloValuationTechniqueMember2024-10-012024-10-310001642380imdx:MonthlyRentMemberimdx:LeaseAgreementMember2024-01-012024-01-310001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:SchutzMember2025-02-102025-02-100001642380us-gaap:RetainedEarningsMember2024-03-310001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:UnterbergLegacyCapitalLLCMember2024-10-042024-10-040001642380imdx:ChronixMergerMember2024-01-012024-06-300001642380us-gaap:WarrantMember2025-01-012025-06-300001642380us-gaap:WarrantMember2017-02-280001642380imdx:KittedProductsMember2024-01-012024-06-300001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:UnterbergLegacyCapitalLLCMember2025-02-102025-02-100001642380us-gaap:CommonStockMemberimdx:UnderwrittenOfferingMemberimdx:BroadwoodCapitalLPMember2022-04-122022-04-130001642380imdx:TwoThousandTenPlanAndTwoThousandEighteenIncentivePlanActivityMember2025-06-300001642380us-gaap:FairValueInputsLevel3Memberimdx:InsightGeneticsIncMember2024-12-310001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberimdx:LaboratoryDevelopedTestServicesMember2024-01-012024-06-300001642380us-gaap:InProcessResearchAndDevelopmentMemberimdx:DetermaCNIMember2024-01-012024-12-310001642380imdx:OfficeSubleaseAgreementMember2023-08-080001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:PrivatePlacementMember2024-10-042024-10-040001642380us-gaap:FairValueInputsLevel3Memberimdx:ChronixMergerMembersrt:MinimumMemberus-gaap:MeasurementInputExpectedTermMember2025-01-012025-06-300001642380imdx:PerformanceBasedRestrictedStockUnitsMember2024-10-012024-10-310001642380imdx:UnderwrittenOfferingMemberimdx:PuraVidaInvestmentsLLCMember2022-04-130001642380imdx:OfficeLeaseAgreementMember2025-01-020001642380imdx:OfficeLeaseAgreementMember2019-12-230001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberimdx:LaboratoryServicesMember2024-01-012024-06-300001642380imdx:InsightGeneticsIncMember2025-01-012025-06-300001642380us-gaap:WarrantMember2019-10-310001642380us-gaap:FairValueInputsLevel3Memberimdx:ChronixMergerMembersrt:MaximumMemberus-gaap:MeasurementInputExpectedTermMember2024-01-012024-06-300001642380imdx:ChronixMergerMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMembersrt:MinimumMember2025-06-300001642380us-gaap:AccountsPayableMemberimdx:CustomerThreeMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-12-310001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberimdx:OutsideOfUnitedStatesMember2024-01-012024-06-300001642380imdx:MPEEMValuationApproachMemberimdx:DetermaIOMember2024-12-310001642380imdx:BioRadLaboratoriesIncMemberimdx:LaboratoryEquipmentMember2025-01-012025-06-300001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2024-01-012024-06-300001642380us-gaap:RetainedEarningsMember2024-04-012024-06-300001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:ArnoMemberimdx:MrGutfreundMember2023-04-032023-04-030001642380imdx:UnderwrittenOfferingMemberimdx:BroadwoodCapitalLPMembersrt:MaximumMember2022-04-122022-04-130001642380imdx:OfficeSubleaseAgreementMember2025-06-300001642380us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberimdx:InsightGeneticsIncMembersrt:MaximumMember2025-06-300001642380us-gaap:SellingAndMarketingExpenseMember2024-04-012024-06-300001642380imdx:SecuritiesPurchaseAgreementMemberimdx:BioRadLaboratoriesIncMemberus-gaap:CommonStockMember2024-10-042024-10-040001642380country:US2024-01-012024-06-300001642380imdx:BroadwoodPartnersLPMemberimdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2024-10-042024-10-040001642380srt:MaximumMember2025-06-300001642380us-gaap:InProcessResearchAndDevelopmentMemberimdx:DetermaCNIMember2025-01-012025-06-300001642380imdx:PreFundedWarrantMember2025-06-300001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberimdx:KittedProductsMember2024-01-012024-06-3000016423802025-03-310001642380imdx:LaboratoryServicesMember2025-06-300001642380imdx:BioRadLaboratoriesIncMemberimdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2025-02-102025-02-100001642380srt:AsiaPacificMember2024-12-310001642380us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2025-02-100001642380us-gaap:SalesRevenueNetMemberimdx:CompanyCMemberus-gaap:CustomerConcentrationRiskMember2024-04-012024-06-300001642380imdx:TwoThousandTenPlanAndTwoThousandEighteenIncentivePlanActivityMember2025-01-012025-06-300001642380imdx:CostOfRevenuesMember2024-01-012024-06-300001642380us-gaap:RetainedEarningsMember2025-01-012025-06-300001642380us-gaap:WarrantMember2017-03-310001642380us-gaap:RestrictedStockUnitsRSUMemberus-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-300001642380us-gaap:CommonStockMember2025-06-300001642380imdx:ChronixMergerMember2025-01-012025-06-300001642380imdx:SecuritiesPurchaseAgreementMemberimdx:PreFundedWarrantMember2025-02-1000016423802024-04-050001642380imdx:PerformanceBasedRestrictedStockUnitsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-10-012024-10-310001642380us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2025-02-102025-02-100001642380imdx:MPCHoldingsLLCMemberimdx:LeaseAgreementMember2024-01-012024-01-310001642380us-gaap:RestrictedStockUnitsRSUMember2024-04-012024-06-300001642380country:US2025-04-012025-06-300001642380imdx:ChronixMergerMember2025-06-300001642380imdx:RazorStockPurchaseAgreementMemberimdx:RazorGenomicsIncMember2023-02-160001642380us-gaap:CommonStockMember2025-03-310001642380us-gaap:ShareBasedCompensationAwardTrancheTwoMemberimdx:PerformanceBasedRestrictedStockUnitsMemberimdx:MonteCarloValuationTechniqueMember2024-10-012024-10-310001642380srt:EuropeMember2025-04-012025-06-300001642380imdx:LaboratoryDevelopedTestServicesMember2024-01-012024-06-300001642380imdx:SubleasePeriodFiveMemberimdx:OfficeSubleaseAgreementMember2025-01-012025-06-300001642380srt:AsiaPacificMember2024-01-012024-06-300001642380imdx:InvestorsMemberimdx:SecuritiesPurchaseAgreementMemberimdx:SeriesARedeemableConvertiblePreferredStockMember2022-04-122022-04-130001642380us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-06-300001642380imdx:SecuritiesPurchaseAgreementMemberimdx:SeriesARedeemableConvertiblePreferredStockMember2022-04-122022-04-130001642380us-gaap:SalesRevenueNetMemberimdx:CompanyBMemberus-gaap:CustomerConcentrationRiskMember2024-04-012024-06-300001642380us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-06-300001642380imdx:LaboratoryDevelopedTestServicesMember2025-01-012025-06-300001642380us-gaap:FairValueInputsLevel3Membersrt:MinimumMemberus-gaap:MeasurementInputDiscountRateMemberimdx:InsightGeneticsIncMember2024-06-300001642380us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001642380us-gaap:CustomerRelationshipsMember2024-12-310001642380us-gaap:FairValueInputsLevel3Memberimdx:InsightGeneticsIncMember2023-12-310001642380us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-06-300001642380us-gaap:EquipmentMembersrt:MinimumMember2025-06-300001642380imdx:ChronixMergerMemberus-gaap:FairValueInputsLevel3Member2025-01-012025-06-300001642380country:GB2024-12-3100016423802024-04-012024-06-3000016423802023-12-310001642380imdx:TwoThousandTenPlanAndTwoThousandEighteenIncentivePlanActivityMember2024-01-012024-12-310001642380us-gaap:RestrictedStockUnitsRSUMember2025-04-012025-06-300001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberimdx:KittedProductsMember2024-04-012024-06-300001642380us-gaap:RetainedEarningsMember2024-01-012024-06-3000016423802024-01-012024-06-300001642380us-gaap:RestrictedStockUnitsRSUMember2024-04-012024-06-300001642380us-gaap:SalesRevenueNetMemberimdx:CompanyCMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-06-300001642380us-gaap:FairValueInputsLevel3Memberimdx:ChronixMergerMember2025-06-300001642380imdx:KittedProductsMember2024-04-012024-06-300001642380imdx:DetermaCNIMember2024-01-012024-12-310001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMembercountry:US2024-01-012024-06-300001642380imdx:CustomerOneMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-12-310001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberimdx:OutsideOfUnitedStatesMember2024-04-012024-06-300001642380us-gaap:WarrantMember2024-04-012024-06-300001642380us-gaap:RetainedEarningsMember2025-03-310001642380us-gaap:CommonStockMember2024-12-310001642380us-gaap:SeriesAPreferredStockMemberimdx:RegisteredDirectOfferingMember2024-04-152024-04-150001642380us-gaap:FairValueInputsLevel3Memberimdx:ChronixMergerMember2024-12-310001642380us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2024-10-040001642380srt:AsiaPacificMember2025-06-300001642380us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001642380imdx:CostOfRevenuesMember2025-01-012025-06-300001642380us-gaap:FairValueInputsLevel3Memberimdx:ChronixMergerMember2024-06-300001642380us-gaap:RetainedEarningsMember2025-06-300001642380country:US2025-06-300001642380us-gaap:CommonStockMember2025-01-012025-06-300001642380us-gaap:FairValueInputsLevel3Memberimdx:InsightGeneticsIncMembersrt:MaximumMemberus-gaap:MeasurementInputExpectedTermMember2024-01-012024-06-300001642380imdx:KittedProductsMember2025-04-012025-06-300001642380imdx:TwoThousandEighteenIncentivePlanMember2025-01-012025-06-300001642380us-gaap:RestrictedStockUnitsRSUMemberus-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-06-300001642380imdx:InsightGeneticsIncMember2025-06-300001642380imdx:SubleasePeriodTwoMemberimdx:OfficeSubleaseAgreementMember2025-01-012025-06-300001642380imdx:TwoThousandTenPlanAndTwoThousandEighteenIncentivePlanActivityMember2024-12-310001642380us-gaap:RestrictedStockUnitsRSUMember2025-04-012025-06-3000016423802025-04-012025-06-3000016423802023-08-012023-08-310001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberimdx:LaboratoryDevelopedTestServicesMember2024-04-012024-06-300001642380imdx:SubleasePeriodThreeMemberimdx:OfficeSubleaseAgreementMember2025-01-012025-06-300001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:SeriesAPreferredStockMemberimdx:BroadwoodCapitalLPMember2022-04-122022-04-130001642380imdx:KittedProductsMember2025-06-300001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMemberimdx:SchutzMember2024-10-042024-10-040001642380imdx:KittedProductsMember2025-01-012025-06-300001642380imdx:SecuritiesPurchaseAgreementMemberus-gaap:CommonStockMember2023-04-030001642380us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001642380imdx:MonthlyRentMemberimdx:OfficeLeaseAgreementMember2019-12-232019-12-230001642380imdx:OfficeLeaseAgreementMember2019-12-232019-12-230001642380us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberimdx:KittedProductsMember2025-01-012025-06-300001642380imdx:UnderwrittenOfferingMemberimdx:UnderwritersMemberimdx:PuraVidaInvestmentsLLCMember2022-04-122022-04-130001642380srt:EuropeMember2024-04-012024-06-300001642380imdx:MPEEMValuationApproachMemberimdx:DetermaIOMember2025-01-012025-06-300001642380imdx:SecuritiesPurchaseAgreementMemberimdx:SeriesARedeemableConvertiblePreferredStockMember2022-04-130001642380imdx:MonteCarloValuationTechniqueMember2023-08-012023-08-310001642380imdx:MPEEMValuationApproachMemberimdx:DetermaIOMember2024-01-012024-12-310001642380imdx:UnderwrittenOfferingMembersrt:MaximumMemberimdx:PuraVidaInvestmentsLLCMember2022-04-130001642380imdx:LaboratoryServicesMember2025-01-012025-06-30imdx:Segmentxbrli:pureutr:sqftxbrli:sharesiso4217:USDxbrli:sharesiso4217:USD

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2025


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to __________

Commission File Number: 1-37648

Insight Molecular Diagnostics Inc.

(Exact name of registrant as specified in its charter)


California		27-1041563
(State or other jurisdiction		(I.R.S. Employer
of incorporation or organization)		Identification No.)

2 International Plaza Dr., Suite 510

Nashville, Tennessee 37217

(Address of principal executive offices) (Zip Code)

(949) 409-7600

(Registrant’s telephone number, including area code)

Oncocyte Corporation, 15 Cushing, Irvine, California 92618

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Exchange Act:


Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, no par value	IMDX	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

The number of shares of issuer's common stock, no par value, outstanding as of August 4, 2025 was 28,619,749.

Table of Contents

INSIGHT MOLECULAR DIAGNOSTICS INC.

TABLE OF CONTENTS

For the quarterly period ended June 30, 2025


	Page
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS	2

PART I - FINANCIAL INFORMATION	3

Item 1. Financial Statements	3
CONDENSED CONSOLIDATED BALANCE SHEETS	3
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS	4
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS	5
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SERIES A REDEEMABLE CONVERTIBLE PREFERRED STOCK AND SHAREHOLDERS’ EQUITY	6
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS	8
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	9

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	43

Item 3. Quantitative and Qualitative Disclosures about Market Risk	55

Item 4. Controls and Procedures	55

PART II - OTHER INFORMATION	56

Item 1. Legal Proceedings	56

Item 1A. Risk Factors	56

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	57

Item 3. Defaults Upon Senior Securities	58

Item 4. Mine Safety Disclosures	58

Item 5. Other Information	58

Item 6. Exhibits	59

SIGNATURES	60

Table of Contents

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this Quarterly Report on Form 10-Q (this “Report”) are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Insight Molecular Diagnostics Inc., or iMDx (f/k/a Oncocyte Corporation), along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Any statements that are not historical fact (including, but not limited to statements that contain words such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “strategy,” “target,” “will,” “would” or similar expressions or the negative of such terms) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of iMDx, particularly those mentioned in this Report under Risk Factors and those Risk Factors in Part I, Item 1A. of our most recent Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the Securities and Exchange Commission (“SEC”). Except as required by law, iMDx undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

The forward-looking statements include, among other things, statements about:

•

the timing and potential achievement of future milestones;

•

the timing and our ability to obtain and maintain coverage and reimbursements from the Centers for Medicare and Medicaid Services and other third-party payers;

•

our plans to pursue research and development of diagnostic test candidates;

•

the potential commercialization of diagnostic tests currently in development;

•

the timing and success of future clinical research and the period during which the results of the clinical research will become available;

•

the potential receipt of revenue from current sales of our diagnostic tests and/or diagnostic tests in development;

•

our assumptions regarding obtaining reimbursement and reimbursement rates of our current diagnostic tests and/or diagnostic tests in development;

•

our estimates regarding future orders of tests and our ability to perform a projected number of tests;

•

our estimates and assumptions around the patient populations, market size and price points for reimbursement for our diagnostic tests;

•

our estimates regarding future revenues, operating expenses, and future capital requirements;

•

our intellectual property position;

•

the impact of government laws and regulations; and

•

our competitive position.

Unless the context otherwise requires, all references to “iMDx,” “we,” “us,” “our,” “the Company” or similar words refer to Insight Molecular Diagnostics Inc., together with our consolidated subsidiaries.

The description or discussion, in this Report, of any contract or agreement is a summary only and is qualified in all respects by reference to the full text of the applicable contract or agreement.

iMDx™, DetermaIO™, DetermaCNI™, GraftAssureCore™, GraftAssureIQ™ and GraftAssureDx™ are trademarks of iMDx, regardless of whether the “TM” symbol accompanies the use of or reference to the applicable trademark in this Report.

We have rebranded our VitaGraft assay (VitaGraft Kidney and VitaGraft Liver), which is our lab developed test, under the name GraftAssureCore. We also rebranded our kitted research-use-only assay, GraftAssure, as “GraftAssureIQ,” and our future kitted clinical assay as “GraftAssureDx.”

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

INSIGHT MOLECULAR DIAGNOSTICS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)


	June 30, 2025			December 31, 2024
	(Unaudited)
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	24,287		$	8,636
Accounts receivable, net of allowance for credit losses of $5 and $16, respectively		512			1,613
Inventories		693			410
Deferred financing costs		—			279
Prepaid expenses and other current assets		1,350			821
Total current assets		26,842			11,759
NONCURRENT ASSETS
Right-of-use and financing lease assets, net		2,524			2,757
Machinery and equipment, net, and construction in progress		4,149			3,567
Intangible assets, net		14,600			14,607
Restricted cash		1,700			1,700
Other noncurrent assets		702			691
TOTAL ASSETS	$	50,517		$	35,081

LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)
CURRENT LIABILITIES
Accounts payable	$	1,277		$	2,279
Accrued compensation		1,459			1,939
Accrued royalties		1,116			1,116
Accrued expenses and other current liabilities		571			418
Right-of-use and financing lease liabilities, current		1,540			1,295
Contingent consideration liabilities, current		689			228
Total current liabilities		6,652			7,275
NONCURRENT LIABILITIES
Right-of-use and financing lease liabilities, noncurrent		1,834			2,369
Contingent consideration liabilities, noncurrent		40,933			37,711
TOTAL LIABILITIES		49,419			47,355

Commitments and contingencies (Note 6)

SHAREHOLDERS’ EQUITY (DEFICIT)
Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding		—			—
Common stock, no par value, 230,000 shares authorized; 28,617 and 17,453 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively		367,965			338,244
Accumulated other comprehensive income		85			21
Accumulated deficit		(366,952	)		(350,539	)
Total shareholders’ equity (deficit)		1,098			(12,274	)
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)	$	50,517		$	35,081

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

INSIGHT MOLECULAR DIAGNOSTICS INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)


	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025			2024
Net revenue	$	518		$	104		$	2,656		$	280

Cost of revenues		168			32			974			141
Cost of revenues – amortization of acquired intangibles		—			22			7			44
Gross profit		350			50			1,675			95

Operating expenses:
Research and development		3,281			2,453			6,205			4,765
Sales and marketing		1,460			853			2,666			1,699
General and administrative		2,647			2,407			5,762			5,080
Change in fair value of contingent consideration		2,804			(1,031	)		3,683			2,281
Impairment loss on held for sale assets		—			—			—			169
Total operating expenses		10,192			4,682			18,316			13,994

Loss from operations		(9,842	)		(4,632	)		(16,641	)		(13,899	)

Other (expenses) income:
Interest expense		(25	)		(8	)		(54	)		(23	)
Other income, net		125			110			282			263
Total other income, net		100			102			228			240

Loss before income taxes		(9,742	)		(4,530	)		(16,413	)		(13,659	)

Income taxes		—			—			—			—

Net loss	$	(9,742	)	$	(4,530	)	$	(16,413	)	$	(13,659	)

Net loss per share (Note 2):
Net loss attributable to common stockholders - basic and diluted	$	(9,742	)	$	(4,587	)	$	(16,413	)	$	(13,922	)
Net loss attributable to common stockholders per share - basic and diluted	$	(0.30	)	$	(0.36	)	$	(0.57	)	$	(1.32	)

Weighted average shares outstanding - basic and diluted		32,023			12,870			28,876			10,567

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

INSIGHT MOLECULAR DIAGNOSTICS INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands)


	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025			2024
Net loss	$	(9,742	)	$	(4,530	)	$	(16,413	)	$	(13,659	)
Foreign currency translation adjustments		44			(3	)		64			(12	)
Comprehensive loss	$	(9,698	)	$	(4,533	)	$	(16,349	)	$	(13,671	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

INSIGHT MOLECULAR DIAGNOSTICS INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SERIES A REDEEMABLE CONVERTIBLE PREFERRED STOCK AND SHAREHOLDERS’ EQUITY

(In thousands)


	Three Months Ended June 30, 2025
	Series A Redeemable Convertible Preferred Stock				Common Stock				Accumulated Other Comprehensive		Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Income		Deficit			Equity
Balance at March 31, 2025		—	$	—		28,599	$	367,387	$	41	$	(357,210	)	$	10,218
Net Loss		—		—		—		—		—		(9,742	)		(9,742	)
Foreign currency translation adjustment		—		—		—		—		44		—			44
Stock-based compensation		—		—		—		504		—		—			504
Vesting of bonus awards		—		—		—		14		—		—			14
Shares issued for consultant services		—		—		18		60		—		—			60
Balance at June 30, 2025		—	$	—		28,617	$	367,965	$	85	$	(366,952	)	$	1,098


	Three Months Ended June 30, 2024
	Series A Redeemable Convertible Preferred Stock						Common Stock					Accumulated Other Comprehensive			Accumulated			Total Shareholders’
	Shares			Amount			Shares		Amount			Income			Deficit			Equity
Balance at March 31, 2024		5		$	5,332			8,273	$	310,553		$	40		$	(299,005	)	$	11,588
Net Loss		—			—			—		—			—			(4,530	)		(4,530	)
Foreign currency translation adjustment		—			—			—		—			(3	)		—			(3	)
Stock-based compensation		—			—			—		386			—			—			386
Vesting of bonus awards		—			—			—		14			—			—			14
Sale of common shares, net of financing costs		—			—			5,077		15,269			—			—			15,269
Shares issued upon vesting of RSUs		—			—			4		—			—			—			—
Shares issued for consultant services		—			—			14		36			—			—			36
Redemption of Series A redeemable convertible preferred stock		(5	)		(5,389	)		—		—			—			—			—
Accretion of Series A convertible preferred stock to redemption value		—			57			—		(57	)		—			—			(57	)
Balance at June 30, 2024		—		$	—			13,368	$	326,201		$	37		$	(303,535	)	$	22,703

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

INSIGHT MOLECULAR DIAGNOSTICS INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SERIES A REDEEMABLE CONVERTIBLE PREFERRED STOCK AND SHAREHOLDERS’ EQUITY

(Continued) (In thousands)


	Six Months Ended June 30, 2025
	Series A Redeemable Convertible Preferred Stock				Common Stock				Accumulated Other Comprehensive		Accumulated			Total Shareholders’
	Shares		Amount		Shares		Amount		Income		Deficit			Equity
Balance at December 31, 2024		—	$	—		17,453	$	338,244	$	21	$	(350,539	)	$	(12,274	)
Net Loss		—		—		—		—		—		(16,413	)		(16,413	)
Foreign currency translation adjustment		—		—		—		—		64		—			64
Stock-based compensation		—		—		—		977		—		—			977
Vesting of bonus awards		—		—		—		28		—		—			28
Sale of common shares, net of financing costs		—		—		11,146		28,656		—		—			28,656
Shares issued for consultant services		—		—		18		60		—		—			60
Balance at June 30, 2025		—	$	—		28,617	$	367,965	$	85	$	(366,952	)	$	1,098


	Six Months Ended June 30, 2024
	Series A Redeemable Convertible Preferred Stock						Common Stock					Accumulated Other Comprehensive			Accumulated			Total Shareholders’
	Shares			Amount			Shares		Amount			Income			Deficit			Equity
Balance at December 31, 2023		5		$	5,126			8,261	$	310,295		$	49		$	(289,876	)	$	20,468
Net loss		—			—			—		—			—			(13,659	)		(13,659	)
Foreign currency translation adjustment		—			—			—		—			(12	)		—			(12	)
Stock-based compensation		—			—			—		804			—			—			804
Vesting of bonus awards		—			—			—		24			—			—			24
Sale of common shares, net of financing costs		—			—			5,077		15,269			—			—			15,269
Shares issued upon vesting of RSUs		—			—			4		—			—			—			—
Shares issued for consultant services		—			—			26		72			—			—			72
Redemption of Series A redeemable convertible preferred stock		(5	)		(5,389	)		—		—			—			—			—
Accretion of Series A convertible preferred stock to redemption value		—			263			—		(263	)		—			—			(263	)
Balance at June 30, 2024		—		$	—			13,368	$	326,201		$	37		$	(303,535	)	$	22,703

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

INSIGHT MOLECULAR DIAGNOSTICS INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)


	Six Months Ended June 30,
	2025			2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(16,413	)	$	(13,659	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense		1,043			617
Amortization of intangible assets		7			44
Stock-based compensation		977			804
Equity compensation for bonus awards and consulting services		88			96
Change in fair value of contingent consideration		3,683			2,281
Impairment loss on held for sale assets		—			169
Changes in operating assets and liabilities:
Accounts receivable		1,101			399
Inventories		(283	)		—
Prepaid expenses and other assets		(189	)		(50	)
Accounts payable and accrued liabilities		(2,086	)		(386	)
Operating lease assets and liabilities		(65	)		(123	)
Net cash used in operating activities		(12,137	)		(9,808	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Machinery and equipment purchases, and construction in progress		(656	)		(215	)
Net cash used in investing activities		(656	)		(215	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common shares		29,143			15,807
Financing costs to issue common shares		(487	)		(538	)
Redemption of Series A redeemable convertible preferred shares		—			(5,389	)
Repayment of financing lease obligations		(212	)		(33	)
Net provided by financing activities		28,444			9,847

NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH		15,651			(176	)

CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING		10,336			11,132
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING	$	25,987		$	10,956

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest	$	45		$	—
Cash paid for income taxes	$	—		$	—

SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES
Machinery and equipment purchases, and construction in progress included in accounts payable and accrued liabilities	$	757		$	26
Accretion of Series A convertible preferred stock	$	—		$	263
Lease assets obtained in exchange for lease liabilities	$	274		$	1,255

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

INSIGHT MOLECULAR DIAGNOSTICS INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Organization and Description of the Business

Insight Molecular Diagnostics Inc. (f/k/a Oncocyte Corporation) (“iMDx,” the “Company,” “we,” “our” or “us”), incorporated in 2009 in California, is a pioneering diagnostics technology company. Our mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Our current intellectual property portfolio comprises three general areas: 1) organ transplant, 2) oncology therapy selection, and 3) oncology therapy monitoring. Within these categories, we have developed or are in the process of developing laboratory developed tests (“LDTs”) that can be run at our Nashville, Tennessee laboratory, kitted research-use-only (“RUO”) tests, and kitted clinical tests that can be run by local labs.

In June 2025, we changed our name from “Oncocyte Corporation” to “Insight Molecular Diagnostics Inc.” Our new trading symbol “IMDX” became effective on the Nasdaq Stock Market, LLC (“Nasdaq”) on June 18, 2025. In addition, in June 2025, we moved our headquarters from Irvine, California, to Nashville, Tennessee, home to our Clinical Laboratory Improvements Amendment (“CLIA”) certified lab and a growing hub for healthcare innovation.

Business Risks

Tariff policies and potential countermeasures could increase our costs and disrupt our global supply chain, which could negatively impact the results of our operations as well as our intangible asset valuations and other fair value measurements. In addition, our business could be adversely impacted by other inflationary factors. The Company will continue to monitor these risks. Refer to Item 1A., “Risk Factors” for additional information about the risks that may impact our business.

Liquidity

iMDx has incurred operating losses and negative operating cash flows since inception and had an accumulated deficit of $367.0 million as of June 30, 2025. iMDx expects to continue to incur operating losses and negative operating cash flows for the foreseeable future. Since its formation, iMDx has financed its operations primarily through the sale of shares of its common stock, convertible preferred stock and warrants to acquire common stock. As of June 30, 2025, iMDx had $24.3 million of cash and cash equivalents and $1.7 million in restricted cash that started to be released in July 2025 (see Note 6, “Office and Facilities Leases – Irvine Office Lease” for additional information).

iMDx received a positive coverage decision from MolDx for GraftAssureCore (Kidney) in August 2023, and it became commercially available for ordering in January 2024 through our CLIA-certified laboratory in Nashville, Tennessee. GraftAssureCore (Kidney) is now broadly available to transplant professionals upon request. In July 2024, iMDx began to commercialize the technology underlying GraftAssureCore (Kidney) by distributing its sister product, GraftAssureIQ, which is intended to be sold and used for research purposes and is labeled as RUO. iMDx expects to distribute its RUO production through a mix of direct sales, partnering and distribution agreements, and licensing. In December 2024, we confirmed Medicare reimbursement for also monitoring certain high-risk patients, that is, those with newly developed donor-specific antibodies. In May 2025, iMDx received another positive coverage decision, which boosted the reimbursement rate per result to $2,753 for GraftAssureCore. In May 2025, iMDx sold its first GraftAssureIQ kits to a research laboratory customer (see Note 2, “Revenue Recognition – Kitted Products” for additional information).

In the field of oncology, iMDx is continuing to develop DetermaIO, a test with promising data supporting its potential to help identify patients likely to respond to checkpoint inhibitor drugs. This new class of drugs modulate the immune response and show activity in multiple solid tumor types including non-small cell lung cancer and triple negative breast cancer. A kitted research product format of the underlying technology began proof-of-concept development in 2023. The application of immunotherapy is a global problem, and thus we expect partnering opportunities for each of our products as they reach clinical maturity. We expect to begin commercializing our oncology product line, which includes DetermaIO, over the next 9 months.

On April 5, 2024, the Company entered into a global strategic partnership agreement with Bio-Rad Laboratories, Inc. (“Bio-Rad”) to collaborate in the development and the commercialization of RUO and in vitro diagnostic (“IVD”) kitted transplant products for clinical use. See Note 10, “Collaborative Arrangements” for additional information. On November 8, 2024, the Company and Bio-Rad entered into a memorandum of understanding with respect to such agreement to establish additional activities to be performed by each party pursuant to such agreement.

Table of Contents

INSIGHT MOLECULAR DIAGNOSTICS INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

On February 10, 2025, the Company consummated a registered direct offering and concurrent private placement of its securities to certain accredited investors (the “February 2025 Offering”). The aggregate gross proceeds from the February 2025 Offering were approximately $29.1 million. After deducting offering expenses payable by the Company of $487,000, the resulting net proceeds were approximately $28.7 million. These net proceeds are inclusive of an investment from Bio-Rad (see Note 9), our aforementioned global strategic partner. See Note 7, “Common Stock – February 2025 Offering” for additional information.

In addition to general economic and capital market trends and conditions, iMDx’s ability to raise sufficient additional capital to finance its operations from time to time will depend on a number of factors specific to iMDx’s operations such as operating revenues and expenses, progress in our collaborative arrangement for the development and the commercialization of RUO and IVD kitted transplant products, progress in obtaining regulatory approval to distribute our products for clinical use, and progress in the development of, or in obtaining reimbursement coverage from Medicare for DetermaIO and other future laboratory tests that iMDx may develop or acquire.

The unavailability or inadequacy of financing or revenues to meet future capital needs could force iMDx to modify, curtail, delay, or suspend some or all aspects of planned operations. Sales of additional equity securities could result in the dilution of the interests of iMDx's current stockholders. iMDx cannot assure that adequate long-term financing will be available on favorable terms, if at all.

In accordance with Accounting Standards Codification (“ASC”) 205-40, Going Concern, we evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements included in this Report are issued. This evaluation initially does not take into consideration the potential mitigating effect of our plans that have not been fully implemented as of the date the consolidated financial statements included in this Report are issued. When substantial doubt exists under this methodology, we evaluate whether the mitigating effect of our plans sufficiently alleviates substantial doubt about our ability to continue as a going concern. The mitigating effect of our plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that such financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about our ability to continue as a going concern within one year after the date that such financial statements are issued. In performing this analysis, we excluded certain elements of our operating plan that cannot be considered probable.

Although it is difficult to predict the Company’s liquidity requirements, based on the going concern evaluation discussed above, management believes that it will have sufficient cash to meet its projected operating requirements for at least the next twelve months following the issuance of these consolidated financial statements. Accordingly, management has concluded that substantial doubt does not exist about the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements. However, the Company anticipates that it may continue to generate operating losses and negative operating cash flows for the foreseeable future as it continues the development of its various programs and incurs additional costs associated with being a public company.

2. Summary of Significant Accounting Policies

Accounting Principles

The consolidated financial statements and accompanying notes are prepared on the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (“GAAP”).

Principles of Consolidation and Basis of Presentation

The unaudited condensed consolidated interim financial statements presented herein have been prepared in accordance with GAAP for financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations, certain information and footnote disclosures normally included in comprehensive audited consolidated financial statements may have been condensed or omitted. The consolidated balance sheet as of December 31, 2024 was derived from the audited consolidated financial statements at that date. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in iMDx’s Annual Report on Form 10-K for the year ended December 31, 2024. The accompanying unaudited condensed consolidated financial statements, in the opinion of management, include all adjustments of a normal recurring nature necessary for a fair presentation of iMDx’s financial condition and results of operations. The consolidated results of operations are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

Table of Contents

INSIGHT MOLECULAR DIAGNOSTICS INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

On January 31, 2020, with the acquisition of Insight Genetics, Inc. (“IGI”) through a merger with a newly incorporated wholly-owned subsidiary of iMDx (the “IGI Merger”) under the terms of an Agreement and Plan of Merger (the “IGI Merger Agreement”), IGI became a wholly-owned subsidiary of iMDx, and on that date iMDx began consolidating IGI’s operations and results with iMDx’s operations and results. See Note 3, “Business Combinations and Contingent Consideration Liabilities – Acquisition of IGI”

On April 15, 2021, with the acquisition of Chronix Biomedical, Inc. (“Chronix”) pursuant to an Agreement and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and restated as of April 15, 2021 (as amended and restated, the “Chronix Merger Agreement”), by and among iMDx and CNI Monitor Sub, Inc., a Delaware corporation and wholly-owned subsidiary of iMDx, Chronix became a wholly-owned subsidiary of iMDx (the “Chronix Merger”), and on that date iMDx began consolidating Chronix’s operations and results with iMDx’s operations and results. See Note 3, “Business Combinations and Contingent Consideration Liabilities – Acquisition of Chronix.”

All material intercompany accounts and transactions have been eliminated in consolidation.

Reclassifications

Certain prior period amounts in the notes to consolidated financial statements have been reclassified to conform to the current period presentation. These changes had no impact on the previously reported consolidated financial condition, results of operations or cash flows.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and contingent assets and liabilities, at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates estimates which are subject to significant judgment, including, but not limited to, valuation methods used, assumptions requiring the use of judgment to prepare financial projections and forecasted financial information, timing of potential commercialization of acquired in-process intangible assets, applicable discount rates, probabilities of the likelihood of multiple outcomes of certain events related to contingent consideration, comparable companies or transactions, determination of fair value of the assets acquired and liabilities assumed (including those relating to contingent consideration), the carrying value of any goodwill and other intangibles and related impairments, assumptions related to going concern assessments, revenue recognition, allowances for credit losses, allocation of direct and indirect expenses, useful lives associated with long-lived intangible and other assets, key assumptions in operating and financing leases including incremental borrowing rates, loss contingencies, valuation allowances related to deferred income taxes, and assumptions used to value stock-based awards and other equity instruments. These assessments are made in the context of information reasonably available to iMDx. Actual results may differ materially from those estimates.

Segment Reporting

In accordance with ASC 280, Segment Reporting, iMDx’s management views its operations as one reportable segment that includes the research, development and commercialization of diagnostic tests, including molecular diagnostic testing products and services. See Note 11 for additional information.

Fair Value Measurements, Business Combinations and Contingent Consideration Liabilities

iMDx accounts for business combinations in accordance with ASC 805, which requires the purchase consideration transferred to be measured at fair value on the acquisition date in accordance with ASC 820, Fair Value Measurement. ASC 820 establishes a single authoritative definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurement. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. ASC 820 describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:

Table of Contents

INSIGHT MOLECULAR DIAGNOSTICS INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

•

Level 1 – Quoted prices in active markets for identical assets and liabilities.

•

Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Such inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. Management estimates include certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs, including the entity’s own assumptions in determining fair value.

When a part of the purchase consideration consists of shares of iMDx common stock, iMDx calculates the purchase price attributable to those shares, a Level 1 security, by determining the fair value of those shares as of the acquisition date based on prices quoted on the principal national securities exchange on which the shares traded. iMDx recognizes estimated fair values of the tangible assets and identifiable intangible assets acquired, including in-process research and development (“IPR&D”), and liabilities assumed, including any contingent consideration, as of the acquisition date. Goodwill is recognized as any amount of excess consideration transferred over the fair value of the tangible and identifiable intangible assets acquired net of the liabilities assumed. ASC 805 precludes the recognition of an assembled workforce as an asset, effectively subsuming any assembled workforce value into goodwill.

In determining fair value, iMDx utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, and also considers counterparty credit risk in its assessment of fair value. As of June 30, 2025 and December 31, 2024, iMDx had no financial assets recorded at fair value on a recurring basis, except for money market funds. These assets are reported as cash equivalents and are measured at fair value using the period-end quoted market prices as a Level 1 input.

The carrying amounts of cash and cash equivalents, restricted cash, net accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate fair values because of the short-term nature of these items.

In accordance with GAAP, from time to time, iMDx measures certain assets at fair value on a nonrecurring basis. iMDx reviews the carrying value of intangibles, including IPR&D (see Note 5), and other long-lived assets for indications of impairment at least annually. Refer to related discussions of impairments below.

Contingent Consideration Liabilities

Certain of iMDx’s asset and business acquisitions involve the potential for future payment of consideration to third-parties and former selling shareholders in amounts determined as a percentage of future net revenues generated, or upon attainment of revenue milestones, from laboratory services or tests, as applicable, or annual minimum royalties to certain licensors, as provided in the applicable agreements. The fair value of such liabilities is determined using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows and the risk-adjusted discount rate used to present value the cash flows. These obligations are referred to as contingent consideration, which are carried at fair value based on Level 3 inputs on a recurring basis.

ASC 805 requires that contingent consideration be estimated and recorded at fair value as of the acquisition date as part of the total consideration transferred. Contingent consideration is an obligation of the acquirer to transfer additional assets or equity interests to the selling shareholders in the future if certain future events occur or conditions are met, such as the attainment of product development milestones. Contingent consideration also includes additional future payments to selling shareholders based on achievement of components of earnings, such as “earn-out” provisions or percentage of future revenues, including royalties paid to the selling shareholders based on a percentage of certain revenues generated.

The fair value of contingent consideration after the acquisition date is reassessed by iMDx as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in the consolidated statements of operations. Changes in key assumptions can materially affect the estimated fair value of contingent consideration liabilities and, accordingly, the resulting gain or loss that iMDx records in its consolidated financial statements. See Note 3 for a full discussion of these liabilities and additional Level 3 fair value disclosures.

Table of Contents

INSIGHT MOLECULAR DIAGNOSTICS INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Cash, Cash Equivalents and Restricted Cash

iMDx considers all highly liquid securities with original maturities of three months or less when purchased to be cash equivalents. For the periods presented, iMDx’s cash equivalents are comprised of investments in AAA rated money market funds that invest in first-tier only securities, which primarily include domestic commercial paper and securities issued or guaranteed by the U.S. government or its agencies. Restricted cash balances, as reported on the consolidated balance sheets, relate to a bank letter of credit required under an office lease arrangement, refer to Note 6 for additional information.

For cashflow reporting purposes, the Company combines the reported balance sheet amounts from cash and cash equivalents with restricted cash (noncurrent). Accordingly, as of June 30, 2025 and 2024, the aggregate amount of such ending balances were $26.0 million and $11.0 million, respectively, as presented on the consolidated statements of cash flows.

Investments in Privately Held Companies

iMDx evaluates whether investments held in common stock of other companies require consolidation of the company under, first, the variable interest entity (“VIE”) model, and then under the voting interest model in accordance with accounting guidance for consolidations under ASC 810-10. If consolidation of the entity is not required under either the VIE model or the voting interest model, iMDx determines whether the equity method of accounting should be applied in accordance with ASC 323, Investments – Equity Method and Joint Ventures. The equity method applies to investments in common stock or in-substance common stock if iMDx exercises significant influence over, but does not control, the entity, where significant influence is typically represented by ownership of 20% or more, but less than majority ownership, of the voting interests of a company. iMDx initially records equity method investments at fair value on the date of the acquisition with subsequent adjustments to the investment balance based on iMDx’s pro rata share of earnings or losses from the investment.

iMDx’s first product for commercial release was a proprietary treatment stratification test called DetermaRx that identifies which patients with early-stage non-small cell lung cancer may benefit from chemotherapy, resulting in a significantly higher, five-year survival rate. Beginning in September 2019 through February 23, 2021, iMDx held a 25% equity interest in Razor Genomics, Inc. (“Razor”), a privately held company, that had developed and licensed to iMDx the lung cancer treatment stratification laboratory test that iMDx was commercializing as DetermaRx. On February 24, 2021, iMDx completed the purchase of all the remaining issued and outstanding shares of common stock of Razor. As a result of the purchase of the Razor common stock, iMDx became the sole shareholder of Razor. On December 15, 2022, the Company entered into a Stock Purchase Agreement (the “Razor Stock Purchase Agreement”) with Dragon Scientific, LLC, a Delaware limited liability company (“Dragon”), and Razor. Pursuant to the Razor Stock Purchase Agreement, iMDx agreed to sell to Dragon, 3,188,181 shares of common stock of Razor, which constituted approximately 70% of the issued and outstanding equity interests of Razor on a fully-diluted basis, and transfer to Razor all of the assets and liabilities related to DetermaRx (the “Razor Sale Transaction”). On February 16, 2023, iMDx completed the Razor Sale Transaction (the “Razor Closing”). In connection with the Razor Closing, iMDx transferred to Razor all of the assets and liabilities related to DetermaRx. While no monetary consideration was received for the sale of 70% of the equity interests of Razor, the transaction allowed the Company to eliminate all development and commercialization costs with respect to DetermaRx. Following the Razor Closing, iMDx continues to own 1,366,364 shares of common stock of Razor, which constitutes approximately 30% of the issued and outstanding equity interests of Razor on a fully-diluted basis, however, the remaining common stock held is accounted for at historical cost less impairment, which is currently zero.

Inventories

Inventories include raw materials, work-in-process and finished goods and are valued at the lower of cost or net realizable value. In September 2024, the Company began to capitalize certain RUO inventory costs in connection with its collaboration arrangement with Bio-Rad to develop and commercialize its GraftAssureIQ RUO kitted tests and eventual IVD kitted transplant testing products. See Note 10, “Collaborative Arrangements” for additional information. As of June 30, 2025, inventories were comprised of raw materials of $424,000 and finished goods of $269,000. As of December 31, 2024, inventories were comprised of raw materials of $207,000 and finished goods of $203,000.

Table of Contents

INSIGHT MOLECULAR DIAGNOSTICS INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Assets Held for Sale

In accordance with ASC subtopic 360-10, Property, Plant, and Equipment, assets and liabilities are classified as held for sale when all of the following criteria for a plan of sale have been met: (1) management, having the authority to approve the action, commits to a plan to sell the assets; (2) the assets are available for immediate sale, in their present condition, subject only to terms that are usual and customary for sales of such assets; (3) an active program to locate a buyer and other actions required to complete the plan to sell the assets have been initiated; (4) the sale of the assets is probable and is expected to be completed within one year; (5) the assets are being actively marketed for a price that is reasonable in relation to their current fair value; and (6) actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. When all of these criteria have been met, the assets and liabilities are classified as held for sale in the consolidated balance sheet. Assets classified as held for sale are reported at the lower of their carrying value or fair value less costs to sell. Depreciation and amortization of assets ceases upon designation as held for sale.

Historically, the Company has entered into agreements to sell certain laboratory equipment. As a result, the Company classified the equipment as held for sale current assets in the consolidated balance sheet, when all the criteria of ASC 360-10 had been met. As such, laboratory equipment was written down to its fair value, less cost to sell, the remainder of which was $32,000 as of June 30, 2024. During the fourth quarter of 2024, the Company placed the remaining equipment items back into service. During the six months ended June 30, 2024, the Company recorded an impairment loss on held for sale assets of $169,000 in the consolidated statement of operations.

Property and Equipment

Machinery and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets, generally over a period of 3 to 10 years. For equipment purchased under financing leases, iMDx amortizes the equipment based on the shorter of the useful life of the equipment or the term of the lease, ranging from 3 to 5 years, depending on the nature and classification of the financing lease (see Note 6). Maintenance and repairs are expensed as incurred whereas significant renewals and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation are removed from the respective accounts and any resulting gain or loss is reflected in iMDx results of operations.

Construction in progress, comprised primarily of leasehold improvements under construction, is not depreciated until the underlying asset is placed into service.

Intangible Assets

In accordance with ASC 350, Intangibles – Goodwill and Other, IPR&D projects acquired in a business combination that are not complete as of the acquisition date are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related research and development efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. iMDx considers various factors and risks for potential impairment of IPR&D assets, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays or inability to obtain local coverage determination (“LCD”) from the Centers for Medicare and Medicaid Services (“CMS”) for Medicare reimbursement for a diagnostic test, the inability to bring a diagnostic test to market and the introduction or advancement of competitors’ diagnostic tests could result in partial or full impairment of the related intangible assets. Consequently, the eventual realized value of the IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods. During the period between completion or abandonment, the IPR&D assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if iMDx becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D projects below their respective carrying amounts.

iMDx does not have intangible assets with indefinite useful lives other than the acquired IPR&D discussed in Note 5, which as of June 30, 2025, has been partially impaired.

Table of Contents

INSIGHT MOLECULAR DIAGNOSTICS INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

In accordance with ASC 350, we review and evaluate our intangible assets for impairment whenever events or changes in circumstances indicate that we may not recover their net book value. When applicable, we test for impairment on an annual basis in the fourth quarter of each year, and between annual tests, if indicators of potential impairment exist, using a fair-value approach. We typically use an income method to estimate the fair value of these assets, which is based on forecasts of the expected future cash flows attributable to the respective assets. Significant estimates and assumptions inherent in the valuations reflect a consideration of other marketplace participants and include the amount and timing of future cash flows (including expected growth rates). Estimates utilized in the projected cash flows include consideration of macroeconomic conditions, overall category growth rates, competitive activities, cost containment and margin expansion, Company business plans, the underlying product or technology life cycles, economic barriers to entry, and the discount rate applied to the cash flows. Unanticipated market or macroeconomic events and circumstances may occur, which could affect the accuracy or validity of the estimates and assumptions.

When applicable, goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill, similar to IPR&D, is not amortized but is tested for impairment at least annually, or if circumstances indicate that it is more-likely-than-not that the carrying value of the associated reporting unit exceeds its fair value. Qualitative factors considered in this assessment include industry and market conditions, overall financial performance, and other relevant events and factors affecting iMDx’s business. Based on the qualitative assessment, if it is determined that the fair value of goodwill is more-likely-than-not to be less than its carrying amount, the fair value of a reporting unit will be calculated and compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value. iMDx continues to operate in one segment (see Note 11) and is considered to be the sole reporting unit and, therefore, goodwill will be tested for impairment at the enterprise level, when applicable.

Long-Lived Intangible Assets

Long-lived intangible assets subject to amortization are stated at acquired cost, less accumulated amortization. iMDx amortizes intangible assets not considered to have an indefinite useful life using the straight-line method over their estimated period of benefit, which generally ranges from 1 to 9 years. Each reporting period, we evaluate the estimated remaining useful life of intangible assets and assess whether events or changes in circumstances warrant a revision to the remaining period of amortization or indicate that impairment exists. Long-lived intangible assets currently consist of acquired customer relationships with an estimated useful life of 5 years (see Note 5).

Impairment of Long-Lived Assets

iMDx’s long-lived assets consist primarily of right-of-use assets for operating and financing leases, machinery and equipment, and finite-lived intangible assets. If events or changes in circumstances indicate that the carrying amount of a long-lived asset may not be recoverable and the expected undiscounted future cash flows attributable to the asset are less than the carrying amount of the asset, an impairment loss, equal to the excess of the carrying value of the asset over its fair value, is recorded.

Leases

iMDx accounts for leases in accordance with ASC 842, Leases. iMDx determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. iMDx accounts for the lease and non-lease components as a single lease component. iMDx recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the consolidated balance sheets. ROU assets represent the right to use an underlying asset during the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most leases do not provide an implicit rate, iMDx uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. iMDx uses the implicit rate when it is readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives. Lease terms may include options to extend or terminate the lease when it is reasonably certain that iMDx will exercise that option. Operating lease expense and financing lease amortization expense are recognized on a straight-line basis over the lease term. Operating leases include ROU office lease assets and related ROU lease liabilities, current and long-term, in the consolidated balance sheets. Financing leases include machinery and equipment and related financing lease liabilities, current and long-term, in the consolidated balance sheets (see “Property and Equipment” above for more information). iMDx discloses the amortization of operating lease ROU assets and the related repayments of ROU lease obligations as a net amount in the consolidated statements of cash flows. iMDx has entered into various operating and financing leases in accordance with ASC 842 as further discussed in Note 6.

Table of Contents

INSIGHT MOLECULAR DIAGNOSTICS INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Accounting for Warrants

iMDx determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, then in accordance with ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock. Under ASC 480, warrants are considered liability classified if the warrants are mandatorily redeemable, obligate iMDx to settle the warrants or the underlying shares by paying cash or other assets, or for warrants that must or may require settlement by issuing a variable number of shares. If warrants do not meet liability classification under ASC 480, iMDx assesses the requirements under ASC 815-40, which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. This liability classification guidance also applies to financial instruments that may require cash or other form of settlement for transactions outside of the company’s control and, in which the form of consideration to the warrant holder may not be the same as to all other shareholders in connection with the transaction. However, if a transaction is not within the company’s control but the holder of the financial instrument can solely receive the same type or form of consideration as is being offered to all the shareholders in the transaction, then equity classification of the financial instrument is not precluded, if all other applicable equity classification criteria are met.

After all relevant assessments, iMDx concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance with all changes in fair value after the issuance date recorded in the consolidated statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. Based on the above guidance and, among other factors, the fact that our warrants cannot be cash settled under any circumstance but require share settlement, all of our outstanding warrants meet the equity classification criteria and have been classified as equity. Refer to Note 7 for details about our outstanding warrants.

Revenue Recognition

Pursuant to ASC 606, Revenue from Contracts with Customers, revenues are recognized when control of goods or services is transferred to customers, in an amount that reflects the consideration iMDx expects to be entitled to in exchange for those goods or services. ASC 606 provides for a five-step model that includes:

(i)

identifying the contract with a customer,

(ii)

identifying the performance obligations in the contract,

(iii)

determining the transaction price,

(iv)

allocating the transaction price to the performance obligations, and

(v)

recognizing revenue when, or as, an entity satisfies a performance obligation.

iMDx determines transaction prices based on the amount of consideration we expect to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. The Company considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.

The following table presents consolidated revenues by type:


	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
	(In thousands)
Laboratory Services	$	494	$	104	$	2,632	$	258
Laboratory Developed Test Services		—		—		—		22
Kitted Products		24		—		24		—
Total	$	518	$	104	$	2,656	$	280

Table of Contents

INSIGHT MOLECULAR DIAGNOSTICS INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Laboratory Services

Revenues recognized include Laboratory Services performed by iMDx for life sciences customers, including testing for biomarker discovery, assay design and development, clinical trial support, and a broad spectrum of biomarker tests. These Laboratory Services are generally performed under individual scope of work (“SOW”) arrangements or license agreements (together with SOW the “Laboratory Services Agreements”) with specific deliverables defined by the customer. Laboratory Services are performed on a (i) time and materials basis or (ii) per test completed basis. Upon completion of the service to the customer in accordance with a Laboratory Services Agreement, iMDx has the right to bill the customer for the agreed upon price (either on a per test or per deliverable basis) and recognizes Laboratory Service revenue at that time. Depending on the Laboratory Services Agreement, iMDx may identify each service of its Laboratory Services offering as a single performance obligation. Offerings include services such as recurring fees for project management, fees for storage and handling, pass through expenses for shipping or calibration, training, proficiency, reproducibility tests, etc. For other Laboratory Services Agreements, iMDx may identify the processing of test samples as a separate performance obligation (considered a series) within license agreements with customers.

Completion of the service and satisfaction of the performance obligation is typically evidenced by acknowledgment of completed services, and access to the report or test made available to the customer or any other form or applicable manner of delivery defined in the Laboratory Services Agreements. However, for certain SOWs under which work is performed pursuant to the customer’s highly customized specifications, iMDx has the enforceable right to bill the customer for work completed, rather than upon completion of the SOW. For those SOWs, iMDx recognizes revenue over a period during which the work is performed using a formula that accounts for expended efforts, generally measured in labor hours, as a percentage of total estimated efforts for the completion of the SOW. As performance obligations are satisfied under the Laboratory Services Agreements, any amounts earned as revenue and billed to the customer are included in accounts receivable. Any revenues earned but not yet billed to the customer as of the date of iMDx’s consolidated financial statements are recorded as contract assets and are included in other current assets as of the financial statement date. Amounts recorded in contract assets are reclassified to accounts receivable in iMDx’s consolidated balance sheets when the customer is invoiced according to the billing schedule in the contract.

As of June 30, 2025 and December 31, 2024, iMDx had gross accounts receivable from Laboratory Services customers of $493,000 and $1.6 million, respectively.

Allowance for Credit Losses

iMDx establishes an allowance for credit losses based on the evaluation of the collectability of its Laboratory Services accounts receivables after considering a variety of factors, including the length of time receivables are past due, significant events that may impair the customer’s ability to pay, such as a bankruptcy filing or deterioration in the customer’s operating results or financial condition, reasonable and supportable forecast that affect the collectability of the reported amount, and historical experience. If circumstances related to customers change, estimates of the recoverability of receivables would be further adjusted. iMDx continuously monitors collections and payments from customers and maintains a provision for estimated credit losses and uncollectible accounts, if any, based upon its historical experience and any specific customer collection issues that have been identified. Amounts determined to be uncollectible are written off against the credit loss reserve accounts. As of June 30, 2025 and December 31, 2024, iMDx had an allowance for credit losses of $5,000 and $16,000, respectively, related to Laboratory Services.

Table of Contents

INSIGHT MOLECULAR DIAGNOSTICS INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Laboratory Developed Test Services

Prior to the Razor Sale Transaction (see “Investments in Privately Held Companies” above), iMDx generated revenue from performing DetermaRx tests on clinical samples through orders received from physicians, hospitals, and other healthcare providers. In determining whether all the revenue recognition criteria in (i) through (v) above was met with respect to DetermaRx tests, each test result was considered a single performance obligation and was generally considered complete when the test result was delivered or made available to the prescribing physician electronically, and, as such, there were no shipping or handling fees incurred by iMDx or billed to customers. Although iMDx billed a list price for all tests ordered and completed for all payer types, iMDx considered constraints on the variable consideration when it recognized revenue for DetermaRx. Because DetermaRx was a novel test and there were no current reimbursement arrangements with third-party payers other than Medicare, the transaction price represented variable consideration. Application of the constraint for variable consideration was an area that required significant judgment. For all payers other than Medicare, iMDx needed to consider the novelty of the test, the uncertainty of receiving payment, or being subject to claims for a refund, from payers with whom it did not have a sufficient payment collection history or contractual reimbursement agreements. Accordingly, for those payers, iMDx recognized revenue upon payment because it had insufficient history to reliably estimate payment patterns. The remaining Medicare and Medicare Advantage accounts receivable net balance was written-off in the first quarter of 2023. Laboratory Developed Test Services revenue recorded during the six months ended June 30, 2024 was the result of payments received.

Kitted Products

Revenues recognized include our GraftAssureIQ RUO kitted tests, which are clearly labeled and intended for research purposes. GraftAssureIQ is a transplant monitoring assay to measure the donor-derived cell-free DNA molecular biomarker. As of June 30, 2025, iMDx had gross accounts receivable from one Kitted Products customer of $24,000, and an allowance for credit losses of less than one thousand dollars. See Note 10, “Collaborative Arrangements” for additional Kitted Products information.

Licensing

Revenues that may be recognized include licensing revenue derived from agreements with customers for exclusive rights to market iMDx’s proprietary testing technology. Under the agreements, iMDx grants exclusive rights to certain trademarks and technology of iMDx for the purpose of marketing iMDx’s tests within a defined geographic territory. A license agreement may specify milestone deliverables or performance obligations, for which iMDx recognizes revenue when its licensee confirms the completion of iMDx’s performance obligation. A licensing agreement may also include ongoing sales support from iMDx and typically includes non-refundable licensing fees and per-test Laboratory Services revenues discussed above, for which iMDx treats the licensing of the technology, trademarks, and ongoing support as a single performance obligation satisfied by the passage of time over the term of the agreement.

Disaggregation of Revenues and Concentrations of Credit Risk

The following table presents the percentage of consolidated revenues by type:


	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025			2024
Laboratory Services		95	%		100	%		99	%		92	%
Laboratory Developed Test Services		0	%		0	%		0	%		8	%
Kitted Products		5	%		0	%		1	%		0	%
Total		100	%		100	%		100	%		100	%

Table of Contents

INSIGHT MOLECULAR DIAGNOSTICS INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The following table presents the percentage of consolidated revenues generated by unaffiliated customers, based on the respective periods presented, that individually represented greater than ten percent of consolidated revenues:


	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025			2024
Company A		95	%		36	%		99	%		52	%
Company B	*				30	%	*				16	%
Company C	*				18	%	*				11	%
Company D	*				16	%	*			*

* Less than 10%

The following table presents the percentage of consolidated revenues attributable to geographical locations, based on country of domicile:


	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025			2024
United States		95	%		65	%		99	%		32	%
Outside of the United States		5	%		35	%		1	%		68	%
Total		100	%		100	%		100	%		100	%

Refer to Note 11, “Segment Reporting” for additional information about geographical revenues and long-lived tangible assets.

Financial instruments that potentially subject the Company to concentrations of credit risk are cash and cash equivalents and accounts receivable. The Company places its cash equivalents primarily in highly rated money market funds. Cash and cash equivalents are also invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. The Company has not experienced any significant losses on its deposits of cash and cash equivalents.

One customer individually represented approximately 95% of accounts receivable as of June 30, 2025. One customer individually represented approximately 97% of accounts receivable as of December 31, 2024. No other customers individually represented greater than ten percent of total accounts receivable.

The Company had accounts payable to two vendors that represented approximately 61% and 26% of accounts payable as of June 30, 2025, and three vendors that represented approximately 37%, 28% and 14% of accounts payable as of December 31, 2024. No other vendors individually represented greater than ten percent of total accounts payable.

The Company has a concentration in the volume of business transacted with Bio-Rad, its global strategic partner. In 2024, the Company entered into an agreement with Bio-Rad to collaborate in the development and the commercialization of RUO and IVD kitted transplant products using Bio-Rad’s ddPCR instruments and reagents, pursuant to which it is dependent on Bio-Rad with respect to many of its ongoing operations and future target performance. See Note 9, “Related Party Transactions – Bio-Rad Transactions” and Note 10, “Collaborative Arrangements” for additional information.

Cost of Revenues

Cost of revenues generally consists of cost of materials, direct labor including benefits, bonus and stock-based compensation, equipment and infrastructure expenses, clinical sample related costs associated with performing Laboratory Services and Laboratory Developed Test Services, providing deliverables according to our licensing agreements, license fees due to third-parties, and amortization of acquired intangible assets such as the customer relationship intangible assets (see Note 5). Infrastructure expenses include depreciation of laboratory equipment, allocated rent costs, leasehold improvements, and allocated information technology costs for operations at iMDx’s CLIA-certified laboratory in Tennessee. Costs associated with generating the revenues are recorded as the tests or services are performed regardless of whether revenue was recognized. Royalties or revenue share payments for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expenses at the time the related revenues are recognized.

Table of Contents

INSIGHT MOLECULAR DIAGNOSTICS INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Research and Development Expenses

Research and development expenses are comprised of costs incurred to develop technology, which include salaries and benefits, stock-based compensation, laboratory expenses (including reagents and supplies used in research and development laboratory work), infrastructure expenses (including depreciation expense and allocated facility occupancy costs), and contract services and other outside costs. Indirect research and development expenses are allocated primarily based on headcount, as applicable, and include rent and utilities, common area maintenance, telecommunications, property taxes and insurance. Research and development costs are expensed as incurred. Certain research and development expenses are attributed to our global strategic collaboration arrangement with Bio-Rad for commercializing our kitted test products. See Note 10, “Collaborative Arrangements” for additional information.

Sales and Marketing Expenses

Sales and marketing expenses consist primarily of personnel costs and related benefits, including stock-based compensation, trade show expenses, branding and positioning expenses, and consulting fees. Sales and marketing expenses also include indirect expenses for applicable overhead allocated based on headcount, and include allocated costs for rent and utilities, common area maintenance, depreciation expense, telecommunications, property taxes and insurance. During the three months ended June 30, 2025 and 2024, iMDx’s total advertising expenses were $166,000 and $44,000, respectively. During the six months ended June 30, 2025 and 2024, iMDx’s total advertising expenses were $257,000 and $83,000, respectively. Certain sales and marketing expenses are attributed to our global strategic collaboration arrangement with Bio-Rad for commercializing our kitted test products. See Note 10, “Collaborative Arrangements” for additional information.

General and Administrative Expenses

General and administrative expenses consist primarily of compensation and related benefits (including stock-based compensation) for executive and corporate personnel, professional and consulting fees, rent and utilities, common area maintenance, depreciation expense, telecommunications, property taxes and insurance. Certain general and administrative expenses are attributed to our global strategic collaboration arrangement with Bio-Rad for commercializing our kitted test products. See Note 10, “Collaborative Arrangements” for additional information.

Stock-Based Compensation

iMDx recognizes compensation expense related to employee, Board of Director and other non-employee option grants and restricted stock grants in accordance with ASC 718, Compensation – Stock Compensation.

iMDx estimates the fair value of stock-based payment awards on the grant date and recognizes the resulting fair value over the requisite service period, which is generally a three or four-year vesting period. For stock-based awards that vest only upon the attainment of one or more performance goals set by iMDx at the time of the grant (sometimes referred to as milestone vesting), compensation cost is recognized if and when iMDx determines that it is probable that the performance condition or conditions will be, or have been, achieved. iMDx uses the Black-Scholes option pricing model for estimating the fair value of time-based options granted under iMDx’s equity plan. The fair value of each restricted stock unit (“RSU”) or award (“RSA”) is determined by the product of the number of units or shares granted and the grant date market price of the underlying common stock. iMDx has elected to treat stock-based payment awards with graded vesting schedules and time-based service conditions as a single award and recognizes stock-based compensation ratably on a straight-line basis over the requisite service period. Options have a maximum contractual term of ten years. Forfeitures are accounted for as they occur. Refer to Note 8 for additional information.

The Black-Scholes option pricing model requires iMDx to make certain assumptions including the expected option term, the expected volatility, the risk-free interest rate and the dividend yield. The expected term of employee stock options represents the weighted average period that the stock options are expected to remain outstanding. iMDx estimates the expected term of options granted based on its own experience. iMDx estimates the expected volatility using its own stock price volatility for a period equal to the expected term of the options. The risk-free interest rate assumption is based upon observed interest rates on the United States government securities appropriate for the expected term of iMDx’s stock options. The dividend yield assumption is based on iMDx’s history and expectation of dividend payouts. iMDx has never declared or paid any cash dividends on its common stock, and iMDx does not anticipate paying any cash dividends in the foreseeable future.

Table of Contents

INSIGHT MOLECULAR DIAGNOSTICS INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

All excess tax benefits and tax deficiencies from stock-based compensation awards accounted for under ASC 718 are recognized as income tax benefit or expense, respectively, in the consolidated statements of operations. An excess income tax benefit arises when the tax deduction of a share-based award for income tax purposes exceeds the compensation cost recognized for financial reporting purposes and, a tax deficiency arises when the compensation cost exceeds the tax deduction. Because iMDx has a full valuation allowance for all periods presented (see “Income Taxes” below), there was no impact to iMDx's consolidated statements of operations for any excess tax benefits or deficiencies, as any excess benefit or deficiency would be offset by the change in the valuation allowance.

Retirement Plan

iMDx has an employee savings and retirement plan under Section 401(k) of the Internal Revenue Code. The plan is a defined contribution plan in which eligible employees may elect to have a percentage of their compensation contributed to the plan, subject to certain guidelines issued by the Internal Revenue Service. During the three months ended June 30, 2025 and 2024, iMDx’s total contributions to the plan were $84,000 and $97,000, respectively. During the six months ended June 30, 2025 and 2024, iMDx’s total contributions to the plan were $161,000 and $167,000, respectively.

Collaborative Arrangements

The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements, which includes determining whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. To the extent that the arrangement falls within the scope of ASC 808, the Company assesses whether the payments between the Company and its collaboration partner fall within the scope of other accounting literature. If the Company concludes that payments from the collaboration partner to the Company would represent consideration from a customer, the Company accounts for those payments within the scope of ASC 606. However, if the Company concludes that its collaboration partner is not a customer for certain activities and associated payments, the Company presents such payments as a reduction of the related expense, based on where the Company presents the underlying expense. See Note 10, “Collaborative Arrangements” for additional information.

Income Taxes

iMDx and its subsidiaries will file a consolidated U.S. federal income tax return and combined California state return for the year ending December 31, 2025. iMDx accounts for income taxes in accordance with ASC 740, Income Taxes, which prescribes the use of the asset and liability method, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect. The provision for income taxes for interim periods is determined using an estimated annual effective tax rate in accordance with ASC 740-270, Income Taxes, Interim Reporting. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective tax rate, including factors such as valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, if any, and changes in or the interpretation of tax laws in jurisdictions where iMDx conducts business.

iMDx did not record any provision or benefit for income taxes for the three and six months ended June 30, 2025 and 2024, as iMDx had a full valuation allowance for the periods presented.

Valuation allowances are established when necessary to reduce deferred tax assets when it is more-likely-than-not that a portion or all of the deferred tax assets will not be realized. iMDx’s judgments regarding future taxable income may change over time due to changes in market conditions, changes in tax laws, tax planning strategies or other factors. If iMDx’s assumptions and consequently its estimates change in the future, the valuation allowance may be increased or decreased, which may have a material impact on iMDx’s consolidated statements of operations. iMDx established a full valuation allowance for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carry-forwards and other deferred tax assets.

The guidance also prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not sustainable upon examination by taxing authorities. iMDx will recognize accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of June 30, 2025 and December 31, 2024. iMDx is not aware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation as of June 30, 2025. iMDx is currently unaware of any tax issues under review. As of June 30, 2025 and December 31, 2024, iMDx had unrecognized tax benefits totaling $1.1 million.

Table of Contents

INSIGHT MOLECULAR DIAGNOSTICS INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

On July 4, 2025, the U.S. enacted H.R. 1, “A bill to provide for reconciliation pursuant to Title II of H. Con. Res. 14,” commonly referred to as the One Big Beautiful Bill. Changes in tax laws may affect recorded deferred tax assets and deferred tax liabilities and iMDx’s effective tax rate in the future. iMDx continues to evaluate the impacts the new legislation will have on the consolidated financial statements. As a result of the enactment of H.R. 1, iMDx anticipates an impact to the deferred tax asset related to the full expensing of domestic research and experimental expenditures in 2025. iMDx does not believe this change had an impact on its consolidated financial statements for the periods ended June 30, 2025.

Net Loss Per Common Share

Basic loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion of the preferred stock, when applicable, by the weighted average number of shares of common stock outstanding during the period. The weighted average shares outstanding - basic in the following table includes the effects of pre-funded warrants that were issued in April 2024 and February 2025 (refer to Note 7, “Common Stock Purchase Warrants” for additional information). Diluted loss per share is computed by dividing the net loss applicable to common stockholders after deducting cumulative unpaid dividends and accretion of the preferred stock, when applicable, by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method or the if-converted method, or the two-class method for participating securities, whichever is more dilutive. Potential common shares are excluded from the computation if their effect is antidilutive.

For the three and six months ended June 30, 2025 and 2024, all common stock equivalents are antidilutive because iMDx reported a net loss. The following table presents the calculation of basic and diluted loss per share of common stock:


	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025			2024
	(In thousands, except per share data)
Numerator:
Net loss	$	(9,742	)	$	(4,530	)	$	(16,413	)	$	(13,659	)
Accretion of Series A redeemable convertible preferred stock		—			(57	)		—			(263	)
Net loss attributable to common stockholders - basic and diluted	$	(9,742	)	$	(4,587	)	$	(16,413	)	$	(13,922	)

Denominator:
Weighted average shares outstanding - basic and diluted		32,023			12,870			28,876			10,567

Net loss per share:
Net loss attributable to common stockholders per share - basic and diluted	$	(0.30	)	$	(0.36	)	$	(0.57	)	$	(1.32	)

Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share:
Stock options		1,084			766			1,084			766
RSUs		792			—			792			—
Warrants		761			773			761			773
Total		2,637			1,539			2,637			1,539

Table of Contents

INSIGHT MOLECULAR DIAGNOSTICS INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Recent Accounting Pronouncements

Not Yet Adopted

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to address investor requests for more transparency about income tax information by requiring improvements to income tax disclosures, including, (i) consistent categories and greater disaggregation of information in the rate reconciliation, and (ii) income taxes paid disaggregated by jurisdiction. Additional amendments in this Update improve the effectiveness and comparability of disclosures by, (i) adding disclosures of pretax income (or loss) and income tax expense (or benefit), and (ii) removing disclosures that no longer are considered cost beneficial or relevant. The amendments in this Update should be applied prospectively (retrospective application is permitted) and are effective for annual periods beginning after December 15, 2024. Management is currently evaluating the impact that the amendments in this Update will have on the Company’s financial statement disclosures. The adoption of this new standard will not have an impact on the Company’s consolidated balance sheets and consolidated statements of operations, comprehensive loss, shareholders' equity (deficit) and cash flows.

In November 2024, the FASB issued ASU No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, to address investor requests for more detailed information about certain types of reported costs and expenses. The amendments in this Update require disclosure, in the notes to financial statements, at each interim and annual reporting period an entity: 1) disclose the amounts of (a) purchases of inventory, (b) employee compensation, (c) depreciation, and (d) intangible asset amortization included in each expense caption presented on the face of the income statement within continuing operations; 2) include certain amounts that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; 3) disclose a qualitative description of the amounts remaining that are not separately disaggregated quantitatively; and 4) disclose the total amount of selling expenses and, in annual reporting periods, an entity’s definition of selling expenses. The amendments in this Update should be applied either prospectively or retrospectively, and are effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027,with early adoption permitted. Management is currently evaluating the impact that the amendments in this Update will have on the Company’s financial statement disclosures. The adoption of this new standard will not have an impact on the Company’s consolidated balance sheets and consolidated statements of operations, comprehensive loss, shareholders' equity (deficit) and cash flows.

3. Business Combinations and Contingent Consideration Liabilities

Acquisition of IGI

On January 31, 2020 (the “IGI Merger Date”), iMDx completed its acquisition of IGI pursuant to the IGI Merger Agreement. iMDx determined there are two types of contingent consideration in connection with the IGI Merger, the Milestone Contingent Consideration and the Royalty Contingent Consideration discussed below.

There were three milestones comprising the Milestone Contingent Consideration, in connection with the IGI Merger which iMDx valued and recorded as part of the contingent consideration as of the IGI Merger Date (see table below), which consisted of (i) a payment for clinical trial completion and related data publication (“Milestone 1”), (ii) a payment for an affirmative final LCD from CMS for a specified lung cancer test (“Milestone 2”), and (iii) a payment for achieving specified CMS reimbursement milestones (“Milestone 3”). If achieved, any respective Milestone will be paid at the contractual value shown below, with the payment made either in cash or in shares of iMDx's common stock as determined by iMDx. There can be no assurance that any of the Milestones will be achieved.

The following table shows the IGI Merger Date contractual payment amounts, as applicable, and the corresponding fair value of each respective contingent consideration liability:


	Contractual Value		Fair Value on the Merger Date
	(In thousands)
Milestone 1	$	1,500	$	1,340
Milestone 2		3,000		1,830
Milestone 3 (a)		1,500		770
Royalty 1 (b)	See(b)			5,980
Royalty 2 (b)	See(b)			1,210
Total	$	6,000	$	11,130

Table of Contents

INSIGHT MOLECULAR DIAGNOSTICS INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(a)

Indicates the maximum amount payable if the Milestone is achieved.

(b)

As defined, Royalty Payments are based on a percentage of future revenues of DetermaIO and Laboratory Services over their respective useful life, accordingly there is no fixed contractual value for the Royalty Contingent Consideration.

The fair value of the contingent consideration after the IGI Merger Date is reassessed by iMDx as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in iMDx’s consolidated statements of operations. Since December 2023, Milestone 1 and Royalty 2 (Laboratory Services) are not expected to be paid and are excluded from the current fair value. During 2025, based on iMDx’s reassessment of significant assumptions, there was a decrease of approximately $73,000 to the fair value of the contingent consideration primarily attributable to revised estimates of the possible future payouts and, accordingly, this amount was recorded as a change in fair value of contingent consideration in the consolidated statement of operations for the six months ended June 30, 2025.

iMDx uses a discounted cash flow valuation technique to determine the fair value of its Level 3 contingent consideration liabilities. The significant unobservable inputs used in IGI’s contingent consideration valuation on June 30, 2025, included: (i) a discount period, based on the expected Milestone payment dates, ranging from 1.7 years to 7.3 years, (ii) a discount rate of 12.6% to 12.9%, and (iii) a management probability estimate of 25% to 50%. The significant unobservable inputs used in IGI’s contingent consideration valuation on June 30, 2024, included: (i) a discount period, based on the expected Milestone payment dates, ranging from 1.7 years to 8.3 years, (ii) a discount rate of 16.0% to 16.7%, and (iii) a management probability estimate of 25% to 50%. Changes to significant unobservable inputs to different amounts could result in a significantly higher or lower fair value measurement at the reporting date.

The following tables reflect the activity for the IGI contingent consideration measured at fair value using Level 3 inputs:


	Fair Value
	(In thousands)
Balance at December 31, 2023	$	2,040
Change in estimated fair value		(73	)
Balance at June 30, 2024	$	1,967

Balance at December 31, 2024	$	2,593
Change in estimated fair value		(73	)
Balance at June 30, 2025	$	2,520

Acquisition of Chronix

On April 15, 2021 (the “Chronix Merger Date”), iMDx completed its acquisition of Chronix pursuant to the Chronix Merger Agreement. As additional consideration for holders of certain classes and series of Chronix capital stock, the Chronix Merger Agreement required iMDx to pay certain contingent consideration. On February 8, 2023, the Company and the equity holder representative named in the Chronix Merger Agreement entered into Amendment No. 1 to the Chronix Merger Agreement, pursuant to which the parties agreed that (i) Chronix’s equity holders will be paid earnout consideration of 10% of net collections for sales of specified tests and products, until the expiration of intellectual property related to such tests and products, (ii) Chronix’s equity holders will be paid 5% of the gross proceeds received from any sale of all or substantially all of the rights, titles, and interests in and to Chronix’s patents for use in transplantation medicine to such third-party, and (iii) all of the previous payment obligations were eliminated.

The fair value of the Chronix contingent consideration after the Chronix Merger Date is reassessed by iMDx as changes in circumstances and conditions occur, with the subsequent change in fair value recorded in iMDx’s consolidated statements of operations. During 2025, based on iMDx’s reassessment of significant assumptions, there was an increase of approximately $3.8 million to the fair value of the contingent consideration primarily attributable to revised estimates of the possible future payouts and, accordingly, this amount was recorded as a change in fair value of contingent consideration in the consolidated statement of operations for the six months ended June 30, 2025.

iMDx uses a discounted cash flow valuation technique to determine the fair value of its Level 3 contingent consideration liabilities. The significant unobservable inputs used in Chronix’s contingent consideration valuation on June 30, 2025, included: (i) a discount period, based on the related patent expiration dates, ranging from 9.3 years to 10.2 years, (ii) a discount rate of 12.6% to 13.2%, and (iii) a payout percentage of 10% based on the earnout provision. The significant unobservable inputs used in Chronix’s contingent consideration valuation on June 30, 2024, included: (i) a discount period, based on the related patent expiration dates, ranging from 9.4

Table of Contents

INSIGHT MOLECULAR DIAGNOSTICS INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

years to 11.2 years, (ii) a discount rate of 16.0% to 17.1%, and (iii) a payout percentage of 10% based on the earnout provision. Changes to significant unobservable inputs to different amounts could result in a significantly higher or lower fair value measurement at the reporting date.

The following tables reflect the activity for the Chronix contingent consideration measured at fair value using Level 3 inputs:


		Fair Value
		(In thousands)
Balance at December 31, 2023

Insight Molecular Diagnostics Inc. 10-Q